Related Experiment Video
Updated: Jan 11, 2026
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Immunotherapy of chimeric antigen receptor NK cells: status and its promising future
Fang Wang1, Zhaoyuan Huang1, Xiaoming Feng2,3,4
1Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Abstract:
Chimeric antigen receptors (CARs) are genetically engineered fusion proteins composed of extracellular antigen-recognition domains and multiple intracellular signaling domains. Although CAR T-cell immunotherapy has achieved significant advancements in treating hematologic malignancies, its application against solid tumors remains less successful. Key challenges-including production complexities, the scarcity of tumor-specific antigens, and limitations in cell trafficking and tumor infiltration-continue to impede therapeutic efficacy. Natural killer (NK) cells, essential innate immune lymphocytes, play a critical role in targeting malignant cells. Their unique antigen-recognition mechanisms, potent cytotoxicity, and favorable clinical safety profile position CAR NK cells as a promising alternative for targeted cancer therapy, especially for solid tumors. However, the transient persistence of NK cells in vivo and the technical challenges associated with their preparation currently limit the broader clinical adoption of this approach. This review examines the advantages of CAR NK cells immunotherapy and synthesizes current domestic and international research to advance the understanding of CAR NK cells therapeutics.
Insights
Chimeric antigen receptor (CAR) Natural Killer (NK) cell therapy shows promise for solid tumors, overcoming limitations of CAR T-cells. Research is advancing CAR NK cell development for broader clinical use.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Engineering
Background:
- Chimeric antigen receptor (CAR) T-cell therapy is effective against blood cancers but faces challenges with solid tumors.
- Solid tumors present difficulties including antigen scarcity, cell trafficking, and infiltration limitations.
- Natural Killer (NK) cells offer potential for cancer therapy due to their cytotoxicity and safety profile.
Purpose of the Study:
- To review the advantages of CAR NK cell immunotherapy.
- To synthesize current research on CAR NK cell therapeutics for solid tumors.
- To address challenges hindering CAR NK cell clinical adoption.
Main Methods:
- Review of existing literature on CAR T-cell and CAR NK cell immunotherapies.
- Analysis of challenges in CAR T-cell therapy for solid tumors.
- Examination of NK cell properties and CAR engineering strategies.
Main Results:
- CAR NK cells present a promising alternative for solid tumor treatment.
- NK cells possess inherent cytotoxicity and a favorable safety profile.
- Challenges like in vivo persistence and production complexity need further research.
Conclusions:
- CAR NK cell immunotherapy holds significant potential for treating solid tumors.
- Overcoming NK cell persistence and manufacturing hurdles is crucial for clinical success.
- Further research is needed to optimize CAR NK cell therapeutics.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...